Natriuretic peptides as therapeutic targets.
Natriuretic peptides (atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide) are cardiac and vascular peptides with vasodilatory, diuretic, natriuretic, anti-inflammatory, antifibrotic and antimitogenic actions. Natriuretic peptides are implicated in normal pressure and volume homeostasis and in the defence against excessive increases in overload-related factors, vasopressive and cardiotoxic factors and their impact on the heart, blood vessels and brain. Genetic manipulation studies confirmed the importance of natriuretic peptides in these functions. Natriuretic peptides are metabolised by NPR-C (clearance receptors) and by enzymatic degradation by neutral endopeptidase. Natriuretic peptide levels (mainly brain natriuretic peptide) correlate with left ventricular hypertrophy and with the severity of heart failure, and are reduced by effective treatment, thus used as diagnostic and prognostic tools. Based on the multiple protective effects of natriuretic peptides, pharmacological therapy has been approved and includes potentiating natriuretic peptide levels by intravenous infusion or by inhibition of endogenous natriuretic peptide degradation. Because each approach has its limitations, the field remains open for improvement.
Centre Hospitalier de L'Université de Montréal Research Center, Laboratory of Cardiovascular Biochemistry, 3840 St-Urbain Street (6-816), Montreal, Quebec, Canada. suhayla.mukaddam-daher@umontreal.ca
Suhayla
S
Mukaddam-Daher
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D045265:Natriuretic Peptides / Q000378:metabolism*; D017461:Receptors, Atrial Natriuretic Factor / Q000378:metabolism
D045265:Natriuretic Peptides; D017461:Receptors, Atrial Natriuretic Factor